PA Medical News about Arthritis, Rheumatoid Infliximab

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/04/09

Schuna AA – The addition of infliximab (Remicade—Centocor) to methotrexate resulted in a superior clinical response compared with the addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (RA) who did not respond to 3 to 4 months of methotrexate monotherapy.

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09 Relevance Score: 82%

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09 Relevance Score: 80%

New Treatment Combination Promising for Children with Arthritis
MedLinePlus, 11/03/09 Relevance Score: 80%

Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Cochrane Reviews, 10/12/09 Relevance Score: 80%

Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs
Journal of Rheumatology, 10/05/09 Relevance Score: 79%